Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

XFOR

X4 Pharmaceuticals Inc

Dec 24 • 04:00PM ET

0.5800

Dollar change +0.0029
Percentage change 0.50	%

Healthcare • Biotechnology • USA • NASD

Peers: BMRN RGNX SRRK KRYS PRTA MCRB ADAP CLLS ADVM ONCT

| Held by: IWM VTI IWO VXF VTWO IWC VTWG RSSL IWV UWM

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.09	Insider Own	30.90%	Shs Outstand	168.51M	Perf Week	-19.93%
Market Cap	98.92M	Forward P/E	-	EPS next Y	-0.53	Insider Trans	-1.29%	Shs Float	117.85M	Perf Month	75.00%
Income	-16.76M	PEG	-	EPS next Q	-0.16	Inst Own	35.58%	Short Float	11.20%	Perf Quarter	-8.04%
Sales	1.12M	P/S	88.32	EPS this Y	77.49%	Inst Trans	-1.18%	Short Ratio	4.17	Perf Half Y	-40.85%
Book/sh	0.35	P/B	1.64	EPS next Y	-309.09%	ROA	-9.54%	Short Interest	13.20M	Perf Year	-18.23%
Cash/sh	0.79	P/C	0.73	EPS next 5Y	-	ROE	-26.35%	52W Range	0.26 - 1.60	Perf YTD	-29.46%
Dividend Est.	-	P/FCF	-	EPS past 5Y	73.95%	ROI	-12.27%	52W High	-63.75%	Beta	0.28
Dividend TTM	-	Quick Ratio	4.80	Sales past 5Y	-20.00%	Gross Margin	20.48%	52W Low	122.05%	ATR (14)	0.10
Dividend Ex-Date	-	Current Ratio	4.89	EPS Y/Y TTM	89.36%	Oper. Margin	-11654.94%	RSI (14)	53.39	Volatility	19.29% 19.00%
Employees	93	Debt/Eq	1.31	Sales Y/Y TTM	-	Profit Margin	-1492.34%	Recom	1.00	Target Price	3.05
Option/Short	Yes / Yes	LT Debt/Eq	1.29	EPS Q/Q	-1461.54%	Payout	-	Rel Volume	0.57	Prev Close	0.58
Sales Surprise	-66.79%	EPS Surprise	-5.02%	Sales Q/Q	-	Earnings	Nov 13 BMO	Avg Volume	3.16M	Price	0.58
SMA20	8.50%	SMA50	15.19%	SMA200	-27.00%	Trades		Volume	1,809,039	Change	0.50%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-12-23	Downgrade	B. Riley Securities	Buy → Neutral	$3 → $1
Aug-30-23	Resumed	B. Riley Securities	Buy	$3
Dec-22-22	Initiated	Cantor Fitzgerald	Overweight	$3
Dec-12-22	Initiated	Piper Sandler	Overweight	$3
Dec-23-19	Initiated	Oppenheimer	Outperform	$20
Dec-18-19	Initiated	ROTH Capital	Buy	$20
Dec-09-19	Upgrade	Citigroup	Neutral → Buy	$16 → $20
Dec-05-19	Initiated	B. Riley FBR	Buy
Jun-07-19	Initiated	Stifel	Buy	$27
Jun-05-19	Initiated	Cowen	Outperform

Dec-04-24 08:00AM	X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting and Exposition (GlobeNewswire)
08:00AM	X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting & Exposition (GlobeNewswire)
Dec-03-24 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-26-24 08:00AM	X4 Pharmaceuticals to Participate in the 36th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-14-24 08:00AM	X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference (GlobeNewswire) +47.85%
02:06AM	Loading…
02:06AM	X4 Pharmaceuticals Inc (XFOR) Q3 2024 Earnings Call Highlights: Strategic Engagement and ... (GuruFocus.com)
Nov-13-24 06:26AM	X4 Pharmaceuticals Posts Wider Loss In Q3 - Quick Facts (RTT News) -53.17%
06:13AM	X4 Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
06:07AM	X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
06:01AM	X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) (GlobeNewswire)
Nov-07-24 11:36AM	The people-first approach transforming eClinical processes (Clinical Trials Arena) +6.53%
Nov-01-24 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-24-24 08:00AM	X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024 (GlobeNewswire)
Oct-01-24 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.09%
Sep-03-24 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.80%
08:00AM	Loading…
Aug-28-24 08:00AM	X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-08-24 06:13AM	X4 Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
06:01AM	X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
Aug-01-24 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -11.16%
Jul-30-24 08:00AM	X4 Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host a Conference Call and Webcast on August 8, 2024 (GlobeNewswire)
Jun-27-24 06:30AM	X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial (GlobeNewswire) -32.99%
Jun-03-24 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.00%
May-29-24 04:30PM	X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia (GlobeNewswire)
May-13-24 08:00AM	X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference (GlobeNewswire) -6.99%
May-09-24 03:59PM	Sector Update: Health Care Stocks Higher Late Afternoon (MT Newswires)
11:52AM	X4 Pharmaceuticals Receives $125 Million Additional Capital; Shares Rise (MT Newswires)
07:29AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
06:30AM	X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility (GlobeNewswire)
May-08-24 11:10AM	X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:14AM	X4 Pharmaceuticals Inc (XFOR) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ... (GuruFocus.com)
10:54AM	Loading…
May-07-24 10:54AM	XFOR Stock Earnings: X4 Pharmaceuticals Misses EPS for Q1 2024 (InvestorPlace) -9.17%
06:07AM	X4 Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
06:01AM	X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
May-01-24 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-30-24 09:32AM	HC Wainwright Adjusts Price Target on X4 Pharmaceuticals to $5 From $3, Maintains Buy Rating (MT Newswires)
08:00AM	X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024 (GlobeNewswire)
Apr-29-24 11:19AM	X4 Pharmaceuticals' Xolremdi Approved by FDA For WHIM Syndrome (MT Newswires) -6.44%
06:47AM	UPDATE 1-US FDA approves X4 Pharmaceuticals' therapy for immunodeficiency disease (Reuters)
06:30AM	X4 Pharmaceuticals Announces FDA Approval of XOLREMDI (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome (GlobeNewswire)
Apr-02-24 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.52%
Apr-01-24 08:00AM	X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences (GlobeNewswire)
Mar-22-24 12:47PM	X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2023 Earnings Call Transcript (Insider Monkey) +11.45%
Mar-21-24 10:09PM	Q4 2023 X4 Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +28.43%
10:53AM	XFOR Stock Earnings: X4 Pharmaceuticals Beats EPS for Q4 2023 (InvestorPlace)
09:11AM	X4 Pharmaceuticals Inc (XFOR) Reports Fourth-Quarter and Full-Year 2023 Financial Results (GuruFocus.com)
06:01AM	X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-12-24 08:00AM	X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024 (GlobeNewswire) -5.23%
Mar-01-24 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-01-24 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.51%
Dec-09-23 12:00PM	X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023 (GlobeNewswire)
Dec-04-23 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +11.05% +8.88%
Nov-10-23 03:46PM	X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q3 2023 Earnings Call Transcript (Insider Monkey) -5.03%
08:00AM	X4 Pharmaceuticals to Participate in Upcoming November Investor Conferences (GlobeNewswire)
01:48AM	Q3 2023 X4 Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-09-23 09:29AM	X4 Pharmaceuticals Inc (XFOR) Reports Q3 2023 Financial Results and Corporate Progress (GuruFocus.com) +6.68%
06:01AM	X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates (GlobeNewswire)
Nov-02-23 08:00AM	X4 Pharmaceuticals to Report Third-Quarter 2023 Financial Results and Host a Conference Call and Webcast on November 9, 2023 (GlobeNewswire) +6.47%
Nov-01-23 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.13%
Oct-31-23 08:00AM	X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in WHIM Syndrome (GlobeNewswire) +9.28%
Oct-18-23 08:00AM	X4 Pharmaceuticals Announces Appointment of Industry Veteran R. Keith Woods to Board of Directors (GlobeNewswire) -5.24%
Oct-02-23 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -9.25% -6.98%
Sep-19-23 08:00AM	X4 Pharmaceuticals to Participate in the Cantor Global Healthcare Conference (GlobeNewswire)
Sep-06-23 08:00AM	X4 Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Sep-05-23 08:00AM	X4 Pharmaceuticals Announces Submission of New Drug Application (NDA) to U.S. FDA for Mavorixafor in WHIM Syndrome (GlobeNewswire)
Sep-01-23 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-15-23 10:53AM	XFOR: NDA for Mavorixafor in WHIM Syndrome in Early 2H23 (Zacks)
Aug-10-23 06:38AM	X4 Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance) -35.98%
06:05AM	X4 Pharmaceuticals Reports Second-Quarter 2023 Financial Results, Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical Program (GlobeNewswire)
Aug-08-23 04:05PM	X4 Pharmaceuticals Announces Industry Veteran Dr. Christophe Arbet-Engels to Join as Chief Medical Officer (GlobeNewswire)
Aug-03-23 08:00AM	X4 Pharmaceuticals Closes $115 Million Loan Facility with Hercules Capital (GlobeNewswire)
Aug-02-23 08:01AM	X4 Pharmaceuticals to Report Second-Quarter 2023 Financial Results and Host a Conference Call and Webcast on August 10, 2023 (GlobeNewswire)
Jun-30-23 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-14-23 06:26AM	XFOR: Initiating Coverage of X4 Pharmaceuticals; Investing on More Than Just a WHIM (Zacks Small Cap Research)
Jun-13-23 08:00AM	X4 Pharmaceuticals Expected to Join Russell 3000® Index (GlobeNewswire) +9.69%
Jun-02-23 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-16-23 04:01PM	X4 Pharmaceuticals Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Duration of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome (GlobeNewswire) +15.79% +25.00%
08:30AM	X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market (GlobeNewswire)
May-15-23 04:44AM	Weekly biotech pulse: X4 Pharma data on deck, AbbVie set for FDA review (Investing.com)
May-04-23 06:12AM	X4 Pharmaceuticals: Q1 Earnings Snapshot (AP Finance)
06:05AM	X4 Pharmaceuticals Reports First-Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-26-23 12:32PM	X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) largest shareholders are retail investors with 42% ownership, institutions own 32% (Simply Wall St.) +11.11%
08:01AM	X4 Pharmaceuticals to Report First-Quarter 2023 Financial Results and Host a Conference Call and Webcast on May 4, 2023 (GlobeNewswire)
Apr-12-23 08:00AM	X4 Pharmaceuticals Announces Late-Breaking Abstract of WHIM Phase 3 Clinical Data Accepted for Oral Presentation at the 2023 Annual Meeting of the Clinical Immunology Society (CIS) (GlobeNewswire) +19.99%
Apr-04-23 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.29%
Mar-24-23 07:36AM	X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-21-23 06:05AM	X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-07-23 08:01AM	X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2022 Financial Results and Host a Conference Call and Webcast on March 21, 2023 (GlobeNewswire) +9.47%
Mar-02-23 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-31-23 12:00PM	What Makes X4 Pharmaceuticals (XFOR) a New Buy Stock (Zacks) +5.67%
Dec-12-22 08:30AM	X4 Pharmaceuticals Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic Neutropenia (GlobeNewswire)
Dec-07-22 08:43AM	X4 Pharmaceuticals Prices $65.0 Million Public Offering (GlobeNewswire) -14.17%
Dec-06-22 06:26PM	X4 Pharmaceuticals Announces Proposed Public Offering (GlobeNewswire) -6.98%
Nov-30-22 08:05AM	X4 Pharmaceuticals Shares Tumble After Phase 3 Data From Rare Immune Deficiency Candidate (Benzinga) -18.92%
Nov-29-22 04:01PM	X4 Pharmaceuticals Announces Positive Top-Line Results from 4WHIM Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in WHIM Syndrome (GlobeNewswire) +5.11%
Nov-17-22 09:51AM	X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) most popular amongst individual investors who own 40% of the shares, institutions hold 34% (Simply Wall St.)
Nov-08-22 08:00AM	X4 Pharmaceuticals to Present at Stifel Healthcare Conference (GlobeNewswire)
Nov-04-22 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-03-22 06:05AM	X4 Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-26-22 08:00AM	X4 Pharmaceuticals Announces Appointment of Industry Veteran Mark Baldry as Chief Commercial Officer (GlobeNewswire)
Oct-20-22 08:00AM	X4 Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host a Conference Call and Webcast to Discuss Important Upcoming Milestones on November 3, 2022 (GlobeNewswire)

X4 Pharmaceuticals, Inc. is a late clinical-stage company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. Its clinical candidate is mavorixafor. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ragan Paula	President and CEO	Nov 15 '24	Sale	0.39	31,897	12,583	993,919	Nov 19 04:31 PM
Ragan Paula	Officer	Nov 15 '24	Proposed Sale	0.41	31,897	13,078		Nov 15 04:12 PM
Ragan Paula	President and CEO	Oct 15 '24	Sale	0.56	31,897	17,926	1,025,816	Oct 16 04:54 PM
Ragan Paula	Officer	Oct 15 '24	Proposed Sale	0.56	31,897	17,862		Oct 15 04:07 PM
Mostafa Adam S.	Chief Financial Officer	Oct 07 '24	Sale	0.55	230,645	126,901	0	Oct 08 04:44 PM
Baldry Mark	Chief Commercial Officer	Oct 07 '24	Sale	0.58	11,127	6,506	48,509	Oct 08 04:44 PM
Ragan Paula	President and CEO	Oct 07 '24	Sale	0.55	239,436	131,522	1,057,713	Oct 08 04:44 PM
DiBiase Mary	Chief Operating Officer	Oct 07 '24	Sale	0.57	67,695	38,329	452,060	Oct 08 04:44 PM
Taveras Arthur	Chief Scientific Officer	Oct 07 '24	Sale	0.56	76,920	43,306	388,026	Oct 08 04:44 PM
DiBiase Mary	Officer	Oct 07 '24	Proposed Sale	0.64	67,695	43,095		Oct 07 04:14 PM
Mostafa Adam S.	Officer	Oct 07 '24	Proposed Sale	0.64	230,645	146,829		Oct 07 04:13 PM
Ragan Paula	Officer	Oct 07 '24	Proposed Sale	0.64	239,436	152,425		Oct 07 04:09 PM
DiBiase Mary	Chief Operating Officer	Sep 09 '24	Sale	0.66	2,642	1,738	289,110	Sep 11 04:01 PM
DiBiase Mary	Officer	Sep 09 '24	Proposed Sale	0.65	2,642	1,728		Sep 09 04:06 PM
Taveras Arthur	Chief Scientific Officer	Mar 11 '24	Sale	0.88	14,235	12,552	234,301	Mar 11 05:20 PM
Ragan Paula	President and CEO	Mar 11 '24	Sale	0.88	49,678	43,856	765,068	Mar 11 05:20 PM
Mostafa Adam S.	Chief Financial Officer	Mar 11 '24	Sale	0.88	52,500	46,347	0	Mar 11 05:19 PM
DiBiase Mary	Chief Operating Officer	Mar 11 '24	Sale	0.88	15,409	13,591	291,752	Mar 11 05:19 PM
DiBiase Mary	Chief Operating Officer	Feb 12 '24	Sale	1.01	3,683	3,709	307,161	Feb 12 05:23 PM
Taveras Arthur	Chief Scientific Officer	Feb 12 '24	Sale	1.01	787	793	248,536	Feb 12 05:23 PM
Ragan Paula	President and CEO	Feb 12 '24	Sale	1.01	21,695	21,892	814,746	Feb 12 05:05 PM
Mostafa Adam S.	Chief Financial Officer	Feb 12 '24	Sale	1.01	27,721	27,973	52,500	Feb 12 05:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

XFOR

X4 Pharmaceuticals Inc

Upgrade your FINVIZ experience